Opinion
Video
Comorbidities and Adherence: Tailoring mHSPC Treatment
Author(s):
Paul E. Dato, MD, discusses how patient-specific factors such as age, tumor volume, comorbidities, and treatment adherence are critical for therapy selection, emphasizing the importance of assessing frailty rather than age alone and the value of multidisciplinary care.
Clinical Brief: Patient-Specific Factors in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Management
Main Discussion Topics
- Beyond Chronological Age: Importance of assessing frailty and performance status using validated scales
- Relevant Comorbidities: Bone density, cardiovascular health, cognitive function, metabolic diseases, and fall risk
- Socioeconomic Considerations: Transportation access, housing status, and caregiver support
- Monitoring Requirements: Regular reassessment of patient status as conditions change over time
Key Points for Physicians
- Proactive monitoring and adjustments are essential to maintain treatment efficacy
- Multidisciplinary care is increasingly important in complex cases
- Consider consultation with cardio-oncology, endocrinology, geriatrics, and bone health specialists
- Treatment optimization is key to enabling patients to remain on therapy and improve outcomes
Notable Insights
The presenter emphasizes that chronological age may not be the best determinant of treatment selection and tolerability, as some 80-year-old patients may be more fit than those 20 years younger.
Clinical Significance
Comprehensive assessment of patient-specific factors beyond disease characteristics is essential for optimizing treatment selection, improving adherence, and maximizing clinical outcomes in metastatic hormone-sensitive prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
